VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Proposed Public Offering of Common Shares
December 12, 2018 16:01 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 09, 2018 07:00 ET | VBI Vaccines, Inc.
­­ -- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively --  -- Encouraging early immunologic data observed in Phase 1/2a study of...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET | VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Responds to Unfounded Allegations in Globes Article
September 16, 2018 01:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 28, 2018 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
August 15, 2018 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference
August 06, 2018 16:15 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
July 09, 2018 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Results of Annual General Meeting
May 25, 2018 16:15 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., May 25, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
May 10, 2018 07:30 ET | VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...